<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(1)</volume><submitter>Kondo T</submitter><pubmed_abstract>&lt;h4>Aims&lt;/h4>Impella has become a new option for mechanical circulatory support in patients with cardiogenic shock (CS); however, prognostic models for patients after Impella are lacking. We aimed to identify the factors that predict in-hospital mortality in patients with CS requiring Impella and develop a new risk prediction model.&lt;h4>Methods and results&lt;/h4>We utilized the J-PVAD registry, which includes all cases where Impella was implanted in Japan. Two-thirds of the patients in the J-PVAD registry were randomly assigned to the derivation cohort (n = 1701), and the other third was assigned to the validation cohort (n = 850). A backward stepwise logistic regression model was developed to identify factors associated with in-hospital mortality. In the derivation cohort, 956 patients were </pubmed_abstract><journal>European journal of heart failure</journal><pagination>51-59</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11798632</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Predicting survival after Impella implantation in patients with cardiogenic shock: The J-PVAD risk score.</pubmed_title><pmcid>PMC11798632</pmcid><pubmed_authors>Imaizumi T</pubmed_authors><pubmed_authors>Morimoto R</pubmed_authors><pubmed_authors>Kondo T</pubmed_authors><pubmed_authors>Mutsuga M</pubmed_authors><pubmed_authors>Kazama S</pubmed_authors><pubmed_authors>Yoshizumi T</pubmed_authors><pubmed_authors>Murohara T</pubmed_authors><pubmed_authors>Hiraiwa H</pubmed_authors><pubmed_authors>Okumura T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predicting survival after Impella implantation in patients with cardiogenic shock: The J-PVAD risk score.</name><description>&lt;h4>Aims&lt;/h4>Impella has become a new option for mechanical circulatory support in patients with cardiogenic shock (CS); however, prognostic models for patients after Impella are lacking. We aimed to identify the factors that predict in-hospital mortality in patients with CS requiring Impella and develop a new risk prediction model.&lt;h4>Methods and results&lt;/h4>We utilized the J-PVAD registry, which includes all cases where Impella was implanted in Japan. Two-thirds of the patients in the J-PVAD registry were randomly assigned to the derivation cohort (n = 1701), and the other third was assigned to the validation cohort (n = 850). A backward stepwise logistic regression model was developed to identify factors associated with in-hospital mortality. In the derivation cohort, 956 patients were </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan</publication><modification>2025-04-04T02:10:20.345Z</modification><creation>2025-04-04T02:10:20.345Z</creation></dates><accession>S-EPMC11798632</accession><cross_references><pubmed>39300761</pubmed><doi>10.1002/ejhf.3471</doi></cross_references></HashMap>